MannKind Corp (MNKD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.33B
Last updated: Nov 17, 2026 at 11:06 AM ET
MannKind Corp (MNKD) Financials: Revenue, Profit and Cash Flow
MannKind reported revenue of $348.97M for the fiscal year ended Dec 31, 2025, up 22.2% from the year before. That year, net income was $5.86M with a net margin of 1.7%, operating cash flow was $18.25M and free cash flow was $13.69M. The quarter ended Sep 30, 2026 had revenue of $101.87M and net income of -$23.22M.
Revenue and Margins
The operating margin was 11.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $174.76M, a compound annual rate of 8.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $348.97M | +22.2% | 74.8% | 11.1% | 1.7% |
| Dec 2024 | $285.50M | +43.5% | 73.2% | 25.4% | 9.7% |
| Dec 2023 | $198.96M | +99.4% | 68.5% | 4.4% | -6.0% |
| Dec 2022 | $99.77M | +32.2% | 42.4% | -64.3% | -87.6% |
| Dec 2021 | $75.44M | +15.8% | 48.5% | -62.3% | -107.3% |
| Dec 2020 | $65.14M | +3.3% | 62.2% | -73.5% | -87.9% |
| Dec 2019 | $63.04M | +126.3% | 55.6% | -70.7% | -82.3% |
| Dec 2018 | $27.86M | +137.2% | 26.5% | -274.9% | -312.2% |
| Dec 2017 | $11.74M | -93.3% | -46.7% | -921.1% | -999.0% |
| Dec 2016 | $174.76M | N/A | 71.3% | 38.5% | 71.9% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 78.8% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $348.97M | $285.50M | $198.96M | $99.77M | $75.44M | $65.14M | $63.04M | $27.86M | $11.74M | $174.76M |
| Cost of revenue | $87.96M | $76.60M | $62.77M | $57.50M | $38.86M | $24.64M | $27.98M | $20.47M | $17.23M | $50.09M |
| Gross profit | $261.01M | $208.90M | $136.19M | $42.27M | $36.59M | $40.50M | $35.06M | $7.39M | -$5.48M | $124.67M |
| Research and development | $66.35M | $45.89M | $31.28M | $19.72M | $12.31M | $19.48M | $6.90M | $8.74M | $14.12M | $14.92M |
| Operating income | $38.80M | $72.59M | $8.68M | -$64.11M | -$47.02M | -$47.91M | -$44.60M | -$76.59M | -$108.19M | $67.26M |
| Net income | $5.86M | $27.59M | -$11.94M | -$87.40M | -$80.93M | -$57.24M | -$51.90M | -$86.97M | -$117.33M | $125.66M |
| EBITDA | $45.73M | $87.01M | $16.55M | -$56.03M | -$41.79M | -$44.56M | -$43.37M | -$74.17M | -$99.16M | $76.19M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $101.87M | $109.37M | $90.17M | $111.95M | $82.13M | $76.53M | $78.35M | $76.78M | $70.08M | $72.39M | $66.26M | $58.47M |
| Gross profit | $78.36M | $79.83M | $72.70M | $82.28M | $61.93M | $55.96M | $60.84M | $57.17M | $52.06M | $52.01M | $47.66M | $40.41M |
| Operating income | -$2.18M | -$350.00K | -$1.67M | -$7.69M | $18.90M | $5.30M | $22.29M | $26.50M | $12.76M | $16.61M | $16.72M | $7.86M |
| Net income | -$23.22M | -$19.03M | -$16.62M | -$15.95M | $7.99M | $668.00K | $13.16M | $7.42M | $11.55M | -$2.01M | $10.63M | $1.40M |
Balance Sheet
As of Dec 2025, total debt of $375.77M exceeded cash and equivalents by $300.89M. Shareholder equity was negative, at -$51.02M, as total liabilities of $843.20M exceeded total assets of $792.18M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $792.18M | $393.84M | $475.20M | $295.28M | $321.16M | $108.61M | $93.72M | $107.70M | $84.58M | $107.06M |
| Current assets | $291.58M | $268.31M | $373.39M | $234.90M | $219.49M | $79.48M | $60.76M | $81.85M | $57.22M | $77.49M |
| Cash and equivalents | $74.88M | $46.34M | $238.48M | $69.77M | $124.18M | $67.00M | $29.91M | $71.16M | $43.95M | $22.89M |
| Total liabilities | $843.20M | $472.66M | $721.37M | $545.82M | $530.51M | $289.03M | $284.25M | $282.79M | $299.31M | $290.66M |
| Short-term debt | $57.41M | $0 | $20.00M | $0 | $6.98M | $4.06M | $5.03M | $11.30M | $52.74M | $71.34M |
| Long-term debt | $318.36M | $36.05M | $248.70M | $273.49M | $281.20M | $118.17M | $113.87M | $91.19M | $104.08M | $77.16M |
| Shareholder equity | -$51.02M | -$78.82M | -$246.17M | -$250.54M | -$209.35M | -$180.42M | -$190.53M | -$175.08M | -$214.73M | -$183.59M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $722.62M | $732.30M | $744.40M | $792.18M | $494.64M | $411.70M | $410.14M | $393.84M | $464.20M | $443.84M | $480.88M | $475.20M |
| Total liabilities | $759.88M | $799.50M | $803.60M | $843.20M | $539.19M | $466.74M | $468.76M | $472.66M | $674.13M | $669.62M | $710.85M | $721.37M |
| Cash and equivalents | $41.28M | $52.93M | $52.83M | $74.88M | $127.39M | $57.01M | $47.31M | $46.34M | $62.37M | $96.64M | $193.27M | $238.48M |
| Shareholder equity | -$37.27M | -$67.20M | -$59.20M | -$51.02M | -$44.55M | -$55.04M | -$58.62M | -$78.82M | -$209.93M | -$225.78M | -$229.97M | -$246.17M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 75.0% of operating cash flow. Share repurchases came to 23.8% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $18.25M | $42.51M | $34.09M | -$80.68M | -$61.71M | -$28.13M | -$88.48M | -$37.73M | -$64.78M | -$78.09M |
| Capital expenditures | $4.57M | $9.69M | $42.44M | $7.59M | $11.47M | $801.00K | $2.56M | $354.00K | $1.14M | $1.14M |
| Free cash flow | $13.69M | $32.82M | -$8.35M | -$88.27M | -$73.17M | -$28.93M | -$91.05M | -$38.09M | -$65.92M | -$79.23M |
| Dividends paid | N/A | N/A | N/A | N/A | $498.00K | $14.87M | $656.00K | N/A | $0 | $0 |
| Share repurchases | $3.26M | $6.09M | $10.27M | $62.00K | $3.12M | $285.00K | $433.00K | $4.23M | $3.31M | $2.69M |
| Investing cash flow | -$304.80M | -$96.65M | -$1.99M | $4.87M | -$151.54M | $15.22M | -$22.84M | -$234.00K | $16.68M | -$1.13M |
| Financing cash flow | $315.10M | -$137.27M | $136.61M | $21.39M | $270.27M | $49.85M | $69.86M | $61.29M | $73.56M | $43.04M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$34.55M | -$18.37M | -$5.37M | -$7.96M | $23.64M | $8.95M | -$6.38M | $22.64M | $9.33M | $3.83M | $6.70M | $21.68M |
| Capital expenditures | $3.21M | $5.08M | $1.88M | $1.99M | $1.13M | $1.12M | $330.00K | $2.90M | $1.42M | $2.97M | $2.41M | $5.87M |
| Free cash flow | -$37.76M | -$23.45M | -$7.25M | -$9.95M | $22.52M | $7.83M | -$6.71M | $19.75M | $7.91M | $861.00K | $4.29M | $15.80M |
Frequently Asked Questions About MNKD
What is MannKind's annual revenue?
MannKind reported revenue of $348.97M for the fiscal year ended Dec 31, 2025.
How fast is MannKind's revenue growing?
Revenue was up 22.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 51.8%.
Is MannKind profitable?
Yes. MannKind reported net income of $5.86M for the fiscal year ended Dec 31, 2025, with a net margin of 1.7%.
How much free cash flow does MNKD generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $18.25M minus capital expenditures of $4.57M produced free cash flow of $13.69M.
How much debt does MannKind have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $318.36M, short-term debt of $57.41M and cash and equivalents of $74.88M.
MNKD pages: Overview, Earnings, Forecast, Financials, Competitors